linjc16/ctgov huggingface dataset:
Inflammatory Profiles of Children at High Risk for Atherosclerosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate levels of inflammatory mediators in children at risk for cardiovascular disease due to family history. We are measuring inflammatory markers in two groups of children and their parents: children with a family history of early atherosclerotic heart disease (cases), and healthy children without such a family history (controls). The design is a cross-sectional study, gathering a fasting blood sample and clinical and behavioral data on children and a parent.

Detailed Description
-----------------
Family history is a well known risk factor for early atherosclerosis. Whether inflammation plays a role in the increased risk of family history is not known. In this prospective single-center study, we are recruiting children with and without a family history of premature atherosclerotic disease, defined as occurring < 55 years in males and <65 years in females. Children are recruited primarily from a pediatric preventive cardiology clinic at Children's Hospital Boston. We measure anthropomorphic characteristics, fasting lipid profiles and inflammatory marker levels, including high sensitivity C-reactive protein (hsCRP), intracellular adhesion molecule 1 (ICAM-1), P-selectin, and tumor necrosis factor alpha receptor 2 (TNFαR2). In this sample of high-risk overweight children, Lp(a) and inflammatory markers could reflect cardiovascular risk outside lipid profiles.

Official Title
-----------------
Inflammatory Profiles of Children at High Risk for Atherosclerosis

Conditions
-----------------
Cardiovascular Disease, Metabolic Syndrome X, Hypercholesterolemia, Inflammation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 8-21 years Parent able to participate Fasting state Live locally Exclusion Criteria: Taking medication that may alter cholesterol levels or inflammatory state Past or present inflammatory illnesses

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Children without family history of early atherosclerosis | |
| 2<br>Children with family history of early atherosclerosis. | |
| 3<br>Parents of children without family history of early atherosclerosis | |
| 4<br>Parents of children with family history of early atherosclerosis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiovascular disease, metabolic syndrome, hypercholesterolemia, child, family history, inflammation
PATET Ratio to Rule Out Transient Tachypnea of the Newborn

Study Overview
=================
Brief Summary
-----------------
This study aims to find out whether diagnosis of Transient Tachypnea of the Newborn(TTN) can be predicted via evaluating pulmonary artery Doppler indices.

Detailed Description
-----------------
Transient Tachypnea of the Newborn(TTN) is the most common diagnosed disease in state of neonatal respiratory distress. However there is not an adequate method to diagnose or rule out TTN. In several studies pulmonary artery Doppler indices are investigated as the possible indicators of pulmonary function. As a result of these studies, physiological processes in fetal lung maturation were established; pulmonary tissue impedance or resistance decreases with increasing gestational age, leading to increased pulmonary blood flow. In a normal lung maturation process the peak sistolic velocity is reached in midsystole, but in case of any reason disturbing the nornal development process,the peak occurs earlier. We suggested that TTN, which is a factor increasing pulmonary tissue impedance like respiratory distress syndrome(RDS) and pulmonary hypoplasia, would change pulmonary artery(PA) Doppler indices, thus by the way of evaluating pulmonary artery Doplerr indices, we could predict possible diagnosis of TTN

Official Title
-----------------
A Non-invasive Method To Rule Out Transient Tachypnea of the Newborn (TTN) : Pulmonary Artery Acceleration to Ejection Time Ratio

Conditions
-----------------
Transient Tachypnea of the Newborn

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Singleton pregnancies who delivered beyond 34 weeks gestational age Exclusion Criteria: fetal abnormality, chronicle maternal disease, pregnancy complication (preeclampsia, diabetes, intrauterine growth restriction,etc.)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TTN positive group<br>The group which subsequently diagnosed as TTN | |
| TTN negative group<br>The group which is not diagnosed as TTN | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PATET ratio | pulmonary artery acceleration to ejection time ratio | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PA PI | pulmonary artery pulsatility index | 2 minutes |
The Effects of Breakfast on Brain Function

Study Overview
=================
Brief Summary
-----------------
To test cognitive abilities of 8-11 year old children under conditions of fasting or receiving a full school breakfast.

Official Title
-----------------
The Effects of Breakfast on Cognitive Functioning

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Dietary Supplement: USDA School Breakfast


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 8-11 years old Between 25th and 95th percentile, BMI-for-age Exclusion Criteria: food allergies or some intolerances uncorrected vision IQ < 80 Other chronic conditions thought to interfere with the study as determined by the investigator

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Fasting | Dietary Supplement: USDA School Breakfast<br>* Breakfast containing 340 calories, 57 g carbohydrate, 14 g protein, 6 g fat.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
School Breakfast, Diet, Nutrition, Brain Function, Cognition, USDA, Healthy Children
Observational Study to Assess Transradial Access for Treatment in the Lower Extremities.

Study Overview
=================
Brief Summary
-----------------
This study is designed to collect data on the complication rates and procedural success of using a transradial access approach to treat peripheral lesions in the lower extremities of a real world population.

Official Title
-----------------
Prospective, Multi-center, Observational, Post-market Study to Assess the Safety and Procedural Success of Performing Transradial Access for Treatment of Atherosclerotic Lesions in the Lower Extremities.

Conditions
-----------------
Peripheral Arterial Disease

Intervention / Treatment
-----------------
* Device: Peripheral Artery Treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Rutherford Category 2-5 Subject scheduled for a transradial intervention to treat a lesion in the lower extremities. Willing to sign consent and agree to follow-up requirements. Exclusion Criteria: Previous failed transradial access attempt Presence of or planned dialysis fistula. Planned amputation Previous or planned transradial access intervention +/- 30 days Radial artery diameter <2.5mm No palpable radial artery Established vasospastic disease Known allergy to contrast that cannot be managed Pregnant or lactating Mentally incompetent or a prisoner Currently participating in a clinical study that has not completed it's primary endpoint

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Treatment of lower extremity lesion via transradial access.<br>Interventions performed are standard of care for treatment of a peripheral lesion. | Device: Peripheral Artery Treatment<br>* Peripheral lesions may be treated by any standard of care methods of treatment.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Radial access site complications | Rates of occurrence in complications associated with transradial access. | Procedure | 
| Procedural Success | Successful completion of intended procedure without access complications and without conversion to femoral access. | Procedure |
Effect of Transversus Abdominis Plane (TAP) Block After Laparoscopic Colon Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effectiveness of Transversus Abdominis Plane (TAP) block as a part of a multimodal postoperative pain management after laparoscopic surgery on colon.

Official Title
-----------------
Effect of Transversus Abdominis Plane (TAP) Block as Postoperative Pain Management After Laparoscopic Colon Surgery

Conditions
-----------------
Laparoscopic Colon Surgery

Intervention / Treatment
-----------------
* Procedure: Transversus abdominis plane (TAP) block
* Procedure: Placebo TAP block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 - 80 BMI 18 - 40 ASA 1 - 3 Written consent Can cooperate Exclusion Criteria: Mb Chron and Collitis Ulcerosa Drug and alcohol abuse Pregnancy Consumption of opioids Drug allergy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Transversus abdominis plane (TAP) block<br>Transversus abdominis plane (TAP) block with ropivacaine | Procedure: Transversus abdominis plane (TAP) block<br>* Bilateral UL-guided TAP block with 20 ml of ropivacaine 0,5%<br>* Other names: Naropin;|
| Placebo Comparator: Block with saline<br>Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane | Procedure: Placebo TAP block<br>* Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane<br>* Other names: Placebo block;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain during cough | VAS-pain score | 6 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain during rest | VAS-pain score at rest | 1,2,4,6,12 and 24 hours | 
| Total opioid consumption | Opioid consumption via PCA-pump. | 0-24 hours | 
| Postoperative nausea and vomiting | Nausea score 0-3 No. of vomits | 1,2,4,6,12,18 and 24 hours |
Outcome of Treating Bladder Cancer in Sohag University Hospital

Study Overview
=================
Brief Summary
-----------------
Retrospective study of outcome of urinary bladder cancer treated in Sohag University hospital in the past 5 years from 2016 to 2020

Detailed Description
-----------------
This study asses the risk factors, prognosis,disease free survival and overall survive rate of treating urinary badder cancer

Official Title
-----------------
Outcome of Treating Urinary Bladder Cancer in Sohag University Hospital Between 2016 to 2020

Conditions
-----------------
Bladder Cancer

Intervention / Treatment
-----------------
* Combination Product: Chemotherapy, Radiotherapy and surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all stages and grades of urinary bladder cancer Any histological types of urinary bladder cancer Exclusion Criteria: presence of other malignancies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Combination Product: Chemotherapy, Radiotherapy and surgery|Trans urethral resection of the tumour or radical cystectomy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease free survival | Time from the end of treatment to the date of first relapse | 2 weeks after treatment to the time of relapse |
Bladder Cancer Detection Using Convolutional Neural Networks

Study Overview
=================
Brief Summary
-----------------
The investigators aim to experiment and implement various deep learning architectures to achieve human-level accuracy in Computer-aided diagnosis (CAD) systems. In particular, the investigators are interested in detecting bladder tumors from CT urography scans and cystoscopies of the bladder in this project.

Detailed Description
-----------------
The investigators aim to experiment and implement various deep learning architectures to achieve human-level accuracy in Computer-aided diagnosis (CAD) systems. In particular, the investigators are interested in detecting bladder tumors from CT urography scans and cystoscopies of the bladder in this project. The investigators want to classify bladder tumors as cancer, non cancer, high grade and low grade, invasive and non-invasive, with high sensitivity and low false positive rate using various convolutional neural networks (CNN). This task can be considered as the first step in building CAD systems for bladder cancer diagnosis. Moreover, by automating this task, the investigator scan significantly reduce the time for the radiologists to create large-scale labeled datasets of CT-urography scans and reduce the false-negative and positive that can happen due to human evaluation cystoscopies.

Official Title
-----------------
Bladder Cancer Detection Using Convolutional Neural Networks

Conditions
-----------------
Bladder Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: Al_bladder


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with first time hematuria Patients with the control program for previous bladder cancer Exclusion Criteria: Patients with control cystoscope for noncancer suspected disease
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Detecting bladder tumor<br>Patients with hematuria, or previous bladder tumor | Diagnostic Test: Al_bladder<br>* Detection of bladder tumor with help of Artificial intelligence<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparing standard technique to Machine Learning | The accuracy of Machine learning to detect bladder cancer compared to standard cystoscopy | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detecting accuracy of subtypes of bladder cancer | The abelity of Machine Learning to identify high grad bladder cancer from low grad bladder cancer | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Machine learning, Artificial intelligence
Effect of Chemotherapy on TMB in NSCLC

Study Overview
=================
Brief Summary
-----------------
Tumor mutation burden is identified as an important biomarkers for predicting PD-1/PD-L1 inhibitors in advanced Non-Small Cell Lung Cancer. Several previous clinical trials have demonstrated that chemotherapy could enhance the efficacy of PD-1/L1 immunotherapy in NSCLC such as Checkmate-227, Impower-150, Keynote-189, etc. Pre-clincial experiment shows that chemotherapy could increase CD8 TIL infiltration in tumor microenvironment, activate T cell immune reaction. However, it remains unclear whether chemotherapy could affect tumor mutation burden in advanced NSCLC patients. The present study aims to evaluate whether tumor mutation burden will change after receiving chemotherapy in advanced NSCLC patients.

Official Title
-----------------
Effect of Platinum-based Chemotherapy on Tumor Mutation Burden in Patients With Advanced Non-small Cell Lung Cancer

Conditions
-----------------
Chemotherapy Effect, Immunotherapy, Tumor Mutation Burden, PD-1/L1 Inhibitor

Intervention / Treatment
-----------------
* Other: Next-Genernation Sequence


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Advanced NSCLC diagnosed histologically; Expected survival ≥ 6 month; Without Druggable molecular events (EGFR, ALK, c-Met, BRAF, Ret, etc) ECOG / PS score: 0-2, and the main organ function to meet the following criteria: HB ≥ 90g / L, ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,BIL <1.5 times the upper limit of normal (ULN); Liver ALT and AST <2.5 × ULN and if liver metastases, ALT and AST <5 × ULN; Serum Cr ≤ 1 × ULN, endogenous creatinine clearance ≥50ml/min Exclusion Criteria: Patient can not comply with research program requirements or follow-up; Patient will receive immunotherapy;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chemotherapy Group<br>All participants are advanced NSCLC without druggable gene mutation (EGFR, ALK, ROS-1, Met, Ret. BRAF, etc), who would receive platinum-based chemotherapy. | Other: Next-Genernation Sequence<br>* Tumor Mutation burden will be evaluated using NGS after 2-cycle chemotherapy, 4-cycle chemotherapy, or at progressive disease<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumor Mutation Burden Change | Tumor mutation burden will be calculated using a 520 genes NGS panel | every 6 weeks up to progression disease |
Evaluation of a Radial Arterial Line's Effect on StO2 Monitoring

Study Overview
=================
Brief Summary
-----------------
Measuring tissue oxygen saturation (St02) in the thenar eminence is emerging as a measurement of resuscitation. However, no study to our knowledge has evaluated the effects of an arterial line in the radial artery supplying this muscle bed on St02. This study will attempt to address the interaction between an arterial line and St02 monitoring in the thenar eminence. As most patients who require aggressive resuscitation will have an arterial line, it is important to understand what if any impact this will have on St02 in the same extremity.

Official Title
-----------------
An Evaluation of a Radial Arterial Line's Effect on StO2 Monitoring Using the InSpectra® Tissue Spectrometer

Conditions
-----------------
Oxygenation

Intervention / Treatment
-----------------
* Device: StO2 monitoring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Standard of care placement of arterial line 18 years of age or older Exclusion Criteria: Pregnant females Nursing mothers Prisoners

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| StO2 values<br>StO2 monitoring | Device: StO2 monitoring<br>* placement of the StO2 device/ external noninvasive<br>* Other names: external near infrared spectroscopy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tissue Oxygen Saturation (StO2) Measurement on the Extremity With a Radial Arterial Line | Using near-infrared spectroscopy, the external device recorded raw StO2 values every 3.5 seconds for approximately 5 minutes prior to and immediately following the insertion of a radial arterial catheter on the ipsilateral side. The raw values were then compiled into one-minute averages. | up to 15 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oxygenation